CSIMarket Company Name, Ticker, Customers, else..
 
Fibrogen Inc   (FGEN)
Other Ticker:  
 
 
Price: $0.7863 $-0.05 -6.504%
Day's High: $0.8751 Week Perf: -0.47 %
Day's Low: $ 0.77 30 Day Perf: -37.1 %
Volume (M): 4,575 52 Wk High: $ 25.69
Volume (M$): $ 3,597 52 Wk Avg: $13.90
Open: $0.85 52 Wk Low: $0.70



 Market Capitalization (Millions $) 77
 Shares Outstanding (Millions) 98
 Employees 832
 Revenues (TTM) (Millions $) 131
 Net Income (TTM) (Millions $) -322
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 3

Fibrogen Inc
Fibrogen Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for the treatment of serious and life-threatening medical conditions. The company was founded in 1993 and is headquartered in San Francisco, California. Fibrogen's pioneering research addresses unmet medical needs in areas such as anemia, fibrosis, and cancer.

Fibrogen's flagship product is roxadustat, a first-in-class oral treatment for anemia in patients with chronic kidney disease. Roxadustat is an hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that increases endogenous erythropoietin levels and enhances iron uptake. Roxadustat is currently approved in China and Japan for the treatment of anemia caused by chronic kidney disease, and the company is pursuing regulatory approval in other markets, including Europe, the United States, and Canada.

In addition to its work on roxadustat, Fibrogen is also developing therapies for other indications. Pamrevlumab, a monoclonal antibody targeting connective tissue growth factor (CTGF), is being evaluated for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy. FG-5200, a gene therapy for cystic fibrosis, is being developed in collaboration with Astellas Pharma.

Fibrogen has an extensive research and development pipeline, with a number of programs in preclinical and clinical stages. The company has partnerships with leading pharmaceutical companies such as AstraZeneca, Astellas, and Bristol-Myers Squibb to develop and commercialize its products. Fibrogen's expertise in hypoxia-inducible factor biology and fibrosis has led to the discovery of novel targets and transformative therapies for unmet medical needs.

Fibrogen has a strong financial position, with a market capitalization of approximately $7 billion as of June 202 The company has over 4,000 employees worldwide and operates research and manufacturing facilities in the United States, China, and Sweden. Fibrogen is committed to research, development, and commercialization of treatments for debilitating and life-threatening diseases, and its innovative therapies have the potential to significantly improve the lives of patients globally.


   Company Address: 409 Illinois Street San Francisco 94158 CA
   Company Phone Number: 978-1200   Stock Exchange / Ticker: NASDAQ FGEN
   FGEN is expected to report next financial results on November 06, 2023.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
      % 
• View Complete Report
   



Cannapharmarx Inc

Cannapharmarx Inc. Shows Promising Results with Reduced Losses and Growing Revenue in First Quarter of 2023



The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
Benitec Biopharma Inc

Benitec Biopharma Inc Revolutionizes the Biotech Industry with Remarkable Q2 2023 Financial Performance!

Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
Kintara Therapeutics Inc

Kintara Therapeutics Inc Faces Challenging Times as Fourth Quarter Earnings Plunge, Sparking Investor Worries

Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
Integrated Biopharma Inc

INBPsn Unveil Latest Financial Results



Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
Rezolute Inc

Major Decline in Company Conduct Signals Troubling Times Ahead

Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.





 

Fibrogen Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com